Overview

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Status:
Completed

Trial end date:
2021-04-29

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Alexey Danilov, MD
OHSU Knight Cancer Institute

Collaborators:

Gilead Sciences
National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Obinutuzumab
Rituximab